Is OMCL a Buy or a Sell? The Bull and Bear Case (2026)

That depends on which case you find more convincing, and both are on this page. The bull case rests on Shift toward recurring software and services, with revenue (fy2025) at ~$1.185 billion (up ~7%). The bear case rests on omnicell's product revenue depends heavily on hospital and health-system capital budgets, which are cyclical and can be cut quickly when providers face financial pressure, making bookings and revenue lumpy. Analysts covering it are spread from $55.00 to $70.00, which is itself a signal that this is genuinely contested. If you believe the thesis, the real questions become sizing and overlap rather than timing. Walnut is not an investment adviser and this is not a recommendation.

Nobody can answer that for you, and the honest version of the question is narrower: has anything changed in the reason you bought it? The bear case on this page is the place to check. Omnicell's product revenue depends heavily on hospital and health-system capital budgets, which are cyclical and can be cut quickly when providers face financial pressure, making bookings and revenue lumpy. If that risk is what you were worried about and it is now playing out, that is a real signal. If the price simply fell while the thesis held, that is a different situation entirely. The most pessimistic published target is $55.00, +29.7% from the $42.40 price, which is one analyst's downside case rather than a floor. Walnut is not an investment adviser.

Shift toward recurring software and services. Omnicell is steering its revenue mix away from one-time hardware sales toward recurring subscription, cloud, and Advanced Services revenue, which it tracks through annual recurring revenue (ARR). The most optimistic analyst target on OMCL is $70.00, +65.1% from the $42.40 price. That figure is only reachable if this thesis works close to its best case.

Omnicell's product revenue depends heavily on hospital and health-system capital budgets, which are cyclical and can be cut quickly when providers face financial pressure, making bookings and revenue lumpy. It competes against larger and better-capitalized rivals, most notably BD (Becton Dickinson) with its Pyxis dispensing line, along with Baxter, Swisslog, and other automation vendors, which can pressure pricing and market share. The company's GAAP profitability has at times been thin relative to its share price, so a large gap between GAAP and non-GAAP earnings and a high trailing P/E leave little room for execution missteps. Long installation and implementation cycles, customer concentration among big health systems, and integration risk from acquisitions add operational uncertainty. Broader healthcare-policy shifts, reimbursement pressure, supply-chain costs, and any product-reliability or regulatory issues around medication safety could also weigh on results. The most pessimistic published target is $55.00, +29.7% from the current price, which is roughly what the stock is worth if these risks bite rather than the drivers.

Omnicell, Inc.

Decide that in advance, because it is far harder to think clearly once a position is moving against you. The concrete tripwires here: the driver behind the bull case (Shift toward recurring software and services) stalling in the reported numbers rather than in the narrative, the risk above (omnicell's product revenue depends heavily on hospital and health-system capital budgets, which are cyclical and can be cut quickly when providers face financial pressure, making bookings and revenue lumpy) turning from a possibility into a reported fact, or the position growing large enough that a bad outcome would matter to your whole portfolio regardless of who is right.

Omnicell is a healthcare-technology company that sells medication-management and pharmacy-automation systems, including automated dispensing cabinets, central-pharmacy robotics, IV compounding automation, and cloud software, to hospitals, health systems, and pharmacies. It earns revenue from both hardware sales and a growing base of recurring service and subscription contracts.

Omnicell generated about $140 million of non-GAAP EBITDA on roughly $1.185 billion of revenue in 2025, and non-GAAP EPS rose sharply in early 2026. Its GAAP earnings, however, have been thin at times, which is why its trailing GAAP P/E has looked very high relative to non-GAAP or normalized measures.

OMCL trades on the Nasdaq, so you can buy whole or fractional shares through any major US broker. Some investors also gain exposure indirectly through healthcare or medical-technology ETFs that hold Omnicell, or by including it as one position in a diversified basket.